Skip to content
Search

Latest Stories

Ranbir Kapoor starrer Animal to release on Dussehra 2022

By Murtuza Iqbal

On 1st January 2021, it was announced that Ranbir Kapoor will be teaming up with Kabir Singh director Sandeep Reddy Vanga for a movie titled Animal. The film will also stars Parineeti Chopra, Anil Kapoor, and Bobby Deol.


Now, today, the makers have announced the release date of the film. Animal will hit the big screens on Dussehra 2022.

T-Series took to Twitter to make an announcement about it. They posted, “#Animal, starring Ranbir Kapoor, Anil Kapoor, Bobby Deol and Parineeti Chopra, directed by Sandeep Reddy Vanga to have a Dusshera 2022 release. Animal is produced by Bhushan Kumar, Pranay Reddy Vanga, Murad Khetani & Krishan Kumar. @AnilKapoor #RanbirKapoor @ParineetiChopra.”

Animal is said to be a gangster drama and reportedly, it also stars Tripti Dimri in a pivotal role. However, the makers have not yet announced her casting officially.

The movie is said to be a crime drama set against the backdrop of a troubled father-son relationship. Reportedly, Anil Kapoor will be seen playing the role of Ranbir’s father in the movie, and Parineeti will be seen portraying the character of Ranbir’s wife. Well, this will be for the first time when we will get to see Ranbir and Parineeti in a film together.

Talking about other films of Ranbir Kapoor, the actor has Brahmastra, Shamshera, and Luv Ranjan’s next lined-up. Shamshera is slated to release on 25th June 2021, and Luv Ranjan’s next will hit the big screens on Holi 2022. Meanwhile, the release date of Brahmastra is not yet announced.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less